Scarica l'app Stockscreener
49.31
2.43%
-1.23
Pre-mercato:
49.19
-0.12
-0.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$50.54
Aprire:
$49.98
Volume 24 ore:
4.06M
Relative Volume:
0.96
Capitalizzazione di mercato:
$98.91B
Reddito:
$43.93B
Utile/perdita netta:
$8.53B
Rapporto P/E:
12.89
EPS:
3.824
Flusso di cassa netto:
$5.74B
1 W Prestazione:
-4.03%
1M Prestazione:
-4.46%
6M Prestazione:
+4.49%
1 anno Prestazione:
+20.18%
Intervallo 1D:
$49.17
$50.14
Intervallo di 1 settimana:
$49.17
$52.11
Portata 52W:
$35.45
$61.70
Gsk Plc Adr Stock (GSK) Company Profile
Nome
Gsk Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare GSK vs LLY, JNJ, ABBV, MRK, AZN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
49.31 | 101.38B | 43.93B | 8.53B | 5.74B | 3.824 |
LLY
Lilly Eli Co
|
1,082.20 | 985.37B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
223.51 | 542.42B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
212.93 | 384.67B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
115.17 | 293.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
179.71 | 287.95B | 60.48B | 10.40B | 8.05B | 3.3297 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-27 | Iniziato | Citigroup | Neutral |
| 2026-01-06 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-11-25 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-06-03 | Downgrade | Berenberg | Buy → Hold |
| 2025-04-15 | Iniziato | Exane BNP Paribas | Neutral |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Downgrade | Jefferies | Buy → Hold |
| 2024-10-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-07-08 | Downgrade | UBS | Buy → Neutral |
| 2024-05-30 | Iniziato | Goldman | Neutral |
| 2024-03-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-02-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2024-01-03 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-03-17 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Ripresa | Goldman | Buy |
| 2023-01-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Downgrade | UBS | Neutral → Sell |
| 2022-09-15 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Ripresa | Citigroup | Neutral |
| 2022-02-11 | Downgrade | DZ Bank | Buy → Hold |
| 2021-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Downgrade | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Iniziato | Deutsche Bank | Hold |
| 2020-11-02 | Aggiornamento | Liberum | Hold → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-02-12 | Downgrade | Shore Capital | Hold → Sell |
| 2020-01-16 | Downgrade | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Iniziato | SVB Leerink | Outperform |
| 2019-11-21 | Aggiornamento | UBS | Neutral → Buy |
| 2019-10-11 | Aggiornamento | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Ripresa | Citigroup | Neutral |
| 2019-09-03 | Aggiornamento | Societe Generale | Sell → Buy |
| 2019-08-13 | Ripresa | JP Morgan | Neutral |
| 2019-06-17 | Ripresa | Morgan Stanley | Underweight |
| 2019-03-08 | Downgrade | Shore Capital | Buy → Hold |
| 2019-02-22 | Downgrade | UBS | Buy → Neutral |
| 2019-01-14 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Ripresa | Jefferies | Buy |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-08-30 | Downgrade | Liberum | Buy → Hold |
| 2018-04-04 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Aggiornamento | Kepler | Reduce → Hold |
Mostra tutto
Gsk Plc Adr Borsa (GSK) Ultime notizie
GSK plc (ADR) stock (GB0009252882): ADR treads water around mid-USD 50s as London shares retreat on - AD HOC NEWS
GSK plc (ADR) stock (GB0009252882): ADR holds steady as investors await next catalysts after recent - AD HOC NEWS
GSK Stock Price, Quote & Chart | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Revenue Breakdown – BCBA:GSK.CI - TradingView
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Earnings and Revenue – BCBA:GSK.CI - TradingView
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Balance Sheet – BCBA:GSK.CI - TradingView
Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035 - GlobeNewswire Inc.
GSK PLC-SPON ADR (NYSE:GSK) Passes Quality-Focused Caviar Cruise Stock Screener with Strong Profitability and Cash Flow - ChartMill
GSK PLC (GSK) Stock Price, Trades & News - GuruFocus
GSK plc stock (GB0009252882): asthma drug progress and Q1 update draw investor focus - AD HOC NEWS
GSK plc stock (GB0009252882): Q1 2026 beat, raised outlook and steady dividend attract fresh attenti - AD HOC NEWS
GSK plc stock (GB0009252882): Fresh 13F filing and annual report keep big pharma in focus - AD HOC NEWS
The Best Healthcare Stocks to Buy - Morningstar
GSK plc (GSK) Stock Price, News, Quote & History - Yahoo Finance
GSK plc stock (GB0009252882): Mixed signals from recent earnings and pipeline updates - AD HOC NEWS
129,513 Shares in GSK PLC Sponsored ADR $GSK Acquired by PFA Pension Forsikringsaktieselskab - MarketBeat
Major holder in GSK (NYSE: GSK) reports 4.93% of voting rights - Stock Titan
GSK PLC Sponsored ADR Announces Quarterly Dividend of $0.44 (NYSE:GSK) - MarketBeat
Vaccine Star Shingrix Lifts GSK, But Weak Segments Raise Eyebrows - Sahm
Elizabeth Warren Calls Trump's '600%' Drug Price Claim Mathematically Impossible: 'His Promise Is As Empty As…' - Sahm
GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth - TradingView
UPDATE 5-GSK shares slide as investors question one-off result boost - Sahm
GSK out-licenses rights for rare liver disease drug to Alfasigma - MSN
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
GSK Forecast, Price Target & Analyst Ratings | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
Gsk Plc Adr Azioni (GSK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):